Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05270044 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Study acronym: COLUMBUS-AD
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 156 to 155v7 Show 1 more changeShow less
    • Study sites: 156 to 155
  2. Study sites: 171 to 156v6
  3. Study sites: 170 to 171v5
  4. Site details revised at 16 of 170 sitesv4
  5. Study sites revised (170)v3 See this version in full on ClinicalTrials.gov ↗
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 170v2 Show 1 more changeShow less
    • Study sites: 0 to 170
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).
Trial Details
NCT Number NCT05270044
Lead Sponsor Pierre Fabre Medicament
Collaborators: European Organisation for Research and Treatment of Cancer - EORTC
Conditions Melanoma
Enrollment 815 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov